markets.businessinsider.com
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Researchers and companies continue exploring new immune-targeted therapies for IBD. A new DR3-targeted antibody could become a future treatment direction if clinical studies show benefit and safety. This announcement signals ongoing drug-discovery activity relevant to people following emerging IBD therapies.
Researchers and clinicians interested in IBD drug development, patients who follow emerging biologic therapies, and investors tracking biotech programs.
What To Know
Shattuck Labs issued a press release announcing a poster presentation at the 2025 Crohn’s and Colitis Congress describing SL-325, a DR3-targeted antagonistic antibody intended for IBD. The company positions SL-325 as a potential first-in-class DR3 antagonist designed to block the TL1A/DR3 pathway.
The poster details will be presented Feb 7 and posted on the company website after the meeting. This is a company announcement about preclinical or early-development research to be presented at a conference, not a clinical guideline or new approved treatment.
It highlights a research program (SL-325) aimed at a specific immune pathway (TL1A/DR3) relevant to inflammatory bowel disease. The press release does not provide clinical results, safety data, or regulatory status and does not indicate that SL-325 is approved for use.
If you want the poster details, watch for the company’s Events and Presentations page or the conference abstracts after Feb 7. For treatment decisions, discuss available approved therapies with your clinician rather than this early-stage program.
This is a company press release about a poster presentation at a scientific meeting; it does not report clinical trial results, approvals, or provide patient-level data. Early-stage research often informs future trials but does not change current treatment options. Review the poster or peer-reviewed publications for detailed methods and data when they become available.
